Information Provided By: 
Fly News Breaks for April 19, 2017
RARE
Apr 19, 2017 | 07:10 EDT
H.C. Wainwright analyst Carol Ann Werther downgraded Ultragenyx Pharmaceuticals to Neutral saying the "best news may be done for some time" after the Phase 3 burosumabtrial study met its primary endpoint. The analyst believes the shares will stay within a trading range from $60 to $80 for the foreseeable future. She lowered her price target for Ultragenyx shares to $72 from $88.
News For RARE From the Last 2 Days
